Antiretroviral adherence and pharmacokinetics: Review of their roles in sustained virologic suppression

AIDS Patient Care and STDs

Volumn 23, Issue 10, 2009, Pages 803-807

  Pham, Paul A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; AMPRENAVIR; AMPRENAVIR PLUS RITONAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; INDINAVIR; INDINAVIR PLUS RITONAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; PATIENT COMPLIANCE; REVIEW; SIDE EFFECT; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VIRAL GENETICS; VIRUS LOAD; VIRUS RESISTANCE;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; PATIENT COMPLIANCE;

EID: 70350114055     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2008.0269     Document Type: Review

References (41)

1. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
2. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clin Infect Dis 2001;33:1417-1423.
3. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr 2000;23:360-361.
4. Glass TR, De Geest S, Weber R, et al. Correlates of selfreported nonadherence to antiretroviral therapy in HIVinfected patients: The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2006;41:385-392.
5. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001;134:968-977.
6. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitor, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000;14:357-366.
7. Carrieri MP, Leport C, Protopopescu C, et al. Factors associated with nonadherence to highly active retroviral therapy- A 5-year follow-up analysis with correction for bias induced by missing data in the treatment maintenance phase. J Acquir Immune Defic Syndr 2006;41:477-485.
8. Lima VD, Harrigan R, Bangsberg DR, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr 2009;50:529.
9. Rueda S, Park-Wyllie LY, Bayoumi AM, et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV=AIDS. Cochrane Database Syst Rev 2006;3:CD001442.
10. Petersen ML, Wang Y, van der Laan MJ, et al. Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: A marginal structural model analysis. Clin Infect Dis 2007; 45:908-915.
11. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: The SWAN Study (AI424-097) 48-week results. Clin Infect Dis 2007;44:1484-1492.
12. Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives in adherence and simplicity for HIV-infected patients on antiretroviral therapy-Self-report of the relative importance of multiple attributes of highly active antiretroviral therapy regimens in predicting adherence. J Acquir Immune Defic Syndr 2004;36:808-816.
13. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:3273-3277; erratum in: JAMA 1989;262:1472.
14. Negredo E, Moltó J, Muñoz-Moreno JA, et al. Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach. Antivir Ther 2004; 9:335-342.
15. Ruane P, Lamg J, DeJesus E, et al. Pilot study of once-daily simplification therapy with abacavir=lamivudine=zidovudine and efavirenz for treatment of HIV-1 infection.HIV Clin Trials 2006;7:229-236.
16. Barrios A, Negredo E, Domingo P, et al. Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: Final results of the EFADITE trial. Antivir Ther 2005;10:825-832.
17. Panel on Clinical Practices for Treatment of HIV Infection, Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, January 29, 2008. HIV=AIDS Treatment Information Service Web site. www.hivatis.org (Last accessed August 23, 2009).
18. Comté L, Vrijens B, Tousset E, et al. Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics. J Pharmacokinet Pharmacodyn 2007;34:549-558.
19. Johnson MA, Gathe JC Jr, Podzamczer D, et al. A once-daily lopinavir=ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr 2006;43:153-160.
20. Mildvan D, Tierney C, Gross A, et al. Randomized comparison in treatment-naílv̈e patients of once-daily vs twice daily lopinavir=ritonavir based ART and comparison of once-daily self-administered vs directly observed therapy. 14th Conference on Retrovirus and Opportunistic Infection (CROI). Session 40, oral abstracts 138. Los Angeles, CA: February 25-28, 2007.
21. Wohl AR, Garland WH, Valencia R, et al. A randomized trial of directly administered antiretroviral therapy and adherence case management intervention. Clin Infect Dis 2006;42:1619-1627.
22. Murphy DA, Wilson CM, Durako SJ, Muenz LR, Belzer M. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort. AIDS Care 2001;13:27-40.
23. Murphy DA, Sarr M, Durako SJ, Moscicki A, Wilson CM, Muenz LR. Barrier to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc 2003;157:249-255.
24. Belzer ME, Fuchs DN, Luftman GS, Tucker DJ. Antiretroviral adherence issues among HIV-positive adolescents and young adults. J Adolesc Health 1999;25:316-319.
25. Williams PL, Storm D, Montepiedra G, et al. Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection. Pediatrics 2006;18:1745-1757.
26. Mellins CA, Brackis-Cott E, Dolezal C, Abrams EJ. The role of psychosocial and family factors in adherence to antiretroviral treatment in human immunodeficiency virusinfected children. Pediatr Infect Dis J 2004;23:1035-1041.
27. King MS, Brun SC, Kempf DJ. Relationship between adherence and the development of resistance in antiretroviralnaive, HIV-1-infected patients receiving lopinavir=ritonavir or nelfinavir. J Infect Dis 2005;191:2046-2052.
28. Shuter J, Sarlo JA, Kanmaz TJ, et al. HIV-infected patients receiving lopinavir=ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr 2007;45:4-8.
29. Gonzalez de Requena D, Bonora S, Canta F, et al. Atazanavir Ctrough is associated with efficacy and safety: definition of therapeutic range [Abstract 645). 12th Conference on Retroviruses Retroviruses and Opportunistic Infections (CROI). Boston, MA: February 22-25, 2005.
30. Sadler BM, Gillotin C, Lou Y, Stein DS. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob Agents Chemother 2001;45:30-37. (Pubitemid 32039089)
31. Burger DM, van Rossum AM, Hugen PW, et al. Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children. Antimicrob Agents Chemother 2001;43:701-705.
32. MacManus S, Yates PJ, Elston RC, et al. GW433908=ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: Absence of protease resistance at 48 weeks. AIDS 2004;18:651-655.
33. Bangsberg RD, Acosta EP, Gupta R, et al. Adherence- resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006;20:223-231.
34. Bangsberg RD. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006;43:939-941.
35. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virological outcomes. Ann Intern Med 2007;146:564-573.
36. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005;191:339-347.
37. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapinebased antiretroviral therapy. N Engl J Med 2004;351:229-240.
38. McIntyre JA, Martinson N, Gray GE. Addition (No.1). of short course Combivir to single dose Viramune for the prevention of mother to child transmission of HIV-1 can significantly decrease the subsequent development of maternal and paediatric NNRTI-resistant virus [Abstract TuFo0204]. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil: July 24-27, 2005.
39. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study. AIDS 2004;18:2391-2400.
40. Riddler SA, Haubrich R, DiRienzo G, et al. Class-sparing regimens for initial treatment of HIV-1 infection. (ACTG 5142). N Engl J Med 2008;358:2095-2106.
41. Shen L, Peterson S, Sedaghat AR, et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti- HIV drugs. Nat Med 2008;14:762-766.